Expression of MTA1 in nasopharyngeal carcinoma and its correlation with prognosis

Medical Oncology

Volumn 31, Issue 12, 2014, Pages 1-8

  Yuan, Taize ^a   Zhang, Huanhuan ^a   Liu, Baoqiong ^b   Zhang, Qiong ^a   Liang, Yin ^a   Zheng, Ronghui ^a   Deng, Jin ^a   Zhang, Xiuping ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Metastases; Metastasis associated protein 1; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; MTA1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER TISSUE; CHEMORADIOTHERAPY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NASOPHARYNX; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PATIENT; PREDICTIVE VALUE; PROTEIN EXPRESSION; RISK FACTOR; SINGLE DRUG DOSE; SURVIVAL RATE; TWO DIMENSIONAL CONVENTIONAL RADIOTHERAPY; CELL NUCLEUS; METABOLISM; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; PROGNOSIS; REFERENCE VALUE; RETROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADULT; AGED; CELL NUCLEUS; CHEMORADIOTHERAPY; FEMALE; HISTONE DEACETYLASES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; REFERENCE VALUES; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84919925952     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0330-z     Document Type: Article

References (25)

1. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx. Accessed 1 Sep 2014.
2. Zeng L, Tian YM, Sun XM, Chen CY, Han F, Xiao WW, Deng XW, Lu TX. Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer. 2014;110(1):49–54.
3. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011;117(9):1874–83.
4. Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M, Xiao F, Fu X, Li J, Zhou B, Long X. Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol. 2012;7:2.
5. Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988;7(2):143–88.
6. Kumar R, Wang RA, Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol. 2003;30(5 Suppl 16):30–7.
7. Weng W, Yin J, Zhang Y, Qiu J, Wang X. Metastasis-associated protein 1 promotes tumor invasion by downregulation of E-cadherin. Int J Oncol. 2014;44(3):812–8.
8. Dias SJ, Zhou X, Ivanovic M, Gailey MP, Dhar S, Zhang L, He Z, Penman AD, Vijayakumar S, Levenson AS. Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Sci Rep. 2013;3:2331.
9. Liu T, Yang M, Yang S, Ge T, Gu L, Lou G. Metastasis-associated protein 1 is a novel marker predicting survival and lymph nodes metastasis in cervical cancer. Hum Pathol. 2013;44(10):2275–81.
10. Tuncay CS, Cimen I, Savas B, Banerjee S. MTA-1 expression is associated with metastasis and epithelial to mesenchymal transition in colorectal cancer cells. Tumour Biol. 2013;34(2):1189–204.
11. Park JO, Jung CK, Sun DI, Joo YH, Kim MS. Relationships between metastasis-associated protein (MTA) 1 and lymphatic metastasis in tonsil cancer. Eur Arch Otorhinolaryngol. 2011;268(9):1329–34.
12. Deng YF, Zhou DN, Ye CS, Zeng L, Yin P. Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis. Ann Otol Rhinol Laryngol. 2012;121(7):457–65.
13. Chan JKC, Bray F, Mccarron P. Nasopharyngeal carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. Pathology and genetics. Head and neck tumours. Lyon: IARC Press; 2005. p. 85–97.
14. Mao YP, Xie FY, Liu LZ, Sun Y, Li L, Tang LL, Liao XB, Xu HY, Chen L, Lai SZ, Lin AH, Liu MZ, Ma J. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):1326–34.
15. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2011;80(3):661–8.
16. Yuan TZ, Zhang HH, Tang QF, Zhang Q, Li J, Liang Y, Huang LJ, Zheng RH, Deng J, Zhang XP. Prognostic value of kisspeptin expression in nasopharyngeal carcinoma. Laryngoscope. 2014;124(5):E167–74.
17. Yao YL, Yang WM. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem. 2003;278(43):42560–8.
18. Toh Y, Pencil SD, Nicolson GL. Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene. 1995;159(1):97–104.
19. Cheng CW, Liu YF, Yu JC, Wang HW, Ding SL, Hsiung CN, Hsu HM, Shieh JC, Wu PE, Shen CY. Prognostic significance of cyclin D1, beta-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Ann Surg Oncol. 2012;19(13):4129–39.
20. Song L, Wang Z, Liu X. MTA1: a prognosis indicator of postoperative patients with esophageal carcinoma. Thorac Cardiovasc Surg. 2013;61(6):479–85.
21. Li WF, Liu N, Cui RX, He QM, Chen M, Jiang N, Sun Y, Zeng J, Liu LZ, Ma J. Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma. J Transl Med. 2012;10(1):78.
22. Ohshiro K, Rayala SK, Wigerup C, Pakala SB, Natha RS, Gururaj AE, Molli PR, Mansson SS, Ramezani A, Hawley RG, Landberg G, Lee NH, Kumar R. Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Rep. 2010;11(9):691–7.
23. Kumar R, Balasenthil S, Manavathi B, Rayala SK, Pakala SB. Metastasis-associated protein 1 and its short form variant stimulates Wnt1 transcription through promoting its derepression from Six3 corepressor. Cancer Res. 2010;70(16):6649–58.
24. Kumar R, Balasenthil S, Pakala SB, Rayala SK, Sahin AA, Ohshiro K. Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells. Cancer Res. 2010;70(16):6598–608.
25. Li S, Tian H, Yue W, Li L, Gao C, Si L, Li W, Hu W, Qi L, Lu M. Down-regulation of MTA1 protein leads to the inhibition of migration, invasion, and angiogenesis of non-small-cell lung cancer cell line. Acta Biochim Biophys Sin (Shanghai). 2013;45(2):115–22.